|  | 
|  | 
| | |  |  | 
 |  | View the full agenda now for the 7th Inflammasome Therapeutics Summit (November | Boston, MA) - the leading event focused on inflammasome-targeted drug development. As clinical data begins to emerge from companies like NodThera, Ventus, and Ventyx, the field is approaching breakthrough moments. Join 70+ experts to explore the latest advances across neuroinflammation, metabolic, and autoimmune diseases, share insights, assess combination therapies, and shape the future of inflammasome-based clinical innovation. | 
 | 
 | 
|  | 
|  | 
| | | By Sergey Jakimov and Artem Trotsyuk, LongeVC |  | In the absence of good data, clear hypotheses, and experimental feedback, AI’s outputs can quickly become unreliable. The solution lies in integrating AI and the scientific method. |  |  | 
 | 
 | 
|  | 
|  | 
|  | 
| | |  |  | Mitigating Gene Editing Risk Comprehensively |  | Webinar | MaxCyte, Inc. |  | A critical challenge for therapeutic programs using CRISPR is managing the risk of off-target effects. Learn how to strengthen the safety of your therapeutic programs with comprehensive assessments. | 
 | 
 | 
|  | 
|  | 
| | |  |  | Multicolor Blood Immunophenotyping With BD Flow System |  | Application Note | By Farzad Oreizy, Angela Chen, Bao Nguyen, et al., BD Biosciences |  | An automated workflow utilizing the BD FACSDuet™ Premium Sample Preparation System integrated with the BD FACSLyric™ Flow Cytometer was assessed and compared to manual processing. | 
 | 
 | 
| | |  |  | Detect Ultra-Rare Variants In cfDNA From Liquid Biopsy Samples |  | Application Note | By Zhong Wu, Krishna Amin, Christa Haldrup, et al., QIAGEN |  | Liquid biopsy, powered by next-generation sequencing, is transforming precision oncology to offer real-time, non-invasive insights into tumor genetics, revolutionizing how we monitor and manage cancer. | 
 | 
 | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  |